Author Correction: PAK4 inhibition improves PD-1 blockade immunotherapy

Nature Cancer

by Gabriel Abril-Rodriguez, Davis Y. Torrejon, Wei Liu, Jesse M. Zaretsky, Theodore S. Nowicki, Jennifer Tsoi, Cristina Puig-Saus, Ignacio Baselga-Carretero, Egmidio Medina, Michael J. Quist, Alejandro J. Garcia, William Senapedis, Erkan Baloglu, Anusha Kalbasi, Gardenia Cheung-Lau, Beata Berent-Maoz, Begoña Comin-Anduix, Siwen Hu-Lieskovan, Cun-Yu Wang, Catherine S. Grasso, Antoni Ribas
October 9, 2026

Blood Cancer Journal

Glucagon-like peptide-1 receptor agonists and risk for hematologic malignancies: a multicenter propensity score-matched analysis

Baptist Health South Florida

Breast Cancer De-Escalation: Defining When Less Treatment Is Enough

The evolution of breast cancer care is increasingly challenging a long-standing assumption in oncology: that greater treatment intensity necessarily translates into better outcomes.

by
October 13, 2026
9 min

Hemasphere

Correction: PAK4 inhibition enhances the efficacy of PD-1 blockade immunotherapy

Original Source(s)

Author Correction: PAK4 inhibition improves PD-1 blockade immunotherapy

Related Content

Glucagon-like peptide-1 receptor agonists and risk for hematologic malignancies: a multicenter propensity score-matched analysis

Breast Cancer De-Escalation: Defining When Less Treatment Is Enough

Immune and cellular determinants of response to HMA-venetoclax regimens in acute myeloid leukemia